Aripiprazole in pervasive developmental disorder not otherwise specified and asperger's disorder: A 14-week, prospective, open-label study

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 3, 2009, Pages 265-274

  Stigler, Kimberly A ^a   Diener, Jonathan T ^a   Kohn, Arlene E ^a   Li, Lang ^a   Erickson, Craig A ^a   Posey, David J ^a   McDougle, Christopher J ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHOLESTEROL; GLUCOSE; LOW DENSITY LIPOPROTEIN; PROLACTIN; TRIACYLGLYCEROL;

ABERRANT BEHAVIOR CHECKLIST; ADOLESCENT; AGGRESSION; ANGER; ARTICLE; ASPERGER SYNDROME; AUTOMUTILATION; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COUGHING; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INCREASED APPETITE; INTELLIGENCE QUOTIENT; IRRITABILITY; LIPOPROTEIN BLOOD LEVEL; MALE; NAUSEA; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; QT INTERVAL; RATING SCALE; RHINITIS; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ASPERGER SYNDROME; BODY MASS INDEX; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FEMALE; HUMANS; IRRITABLE MOOD; MALE; PILOT PROJECTS; PIPERAZINES; PROLACTIN; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUINOLONES; SEVERITY OF ILLNESS INDEX;

EID: 67650895041     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.093     Document Type: Article

References (61)

1. Aman MG, Singh NN: Supplement to Aberrant Behavior Checklist Manual. East Aurora (New York): Slosson EducationalPublications, 1994.
2. Aman MG, Singh NN, Stewart AW, Field CJ: The Aberrant Behavior Checklist: A behavior rating scale for the assessmentof treatment effects. Am J Ment Defic 89:485-491, 1985.
3. Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL: Acute and long term safety and tolerability of risperidone in children with autism. JChild Adolesc Psychopharmacol 25:565-569, 2005.
4. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision.Washington (DC): American Psychiatric Association, 2000.
5. Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, Arnold LE, Martin A, Katsovich L, Posey DJ, Shah B, Vitiello B: Effects of short- and long-term risperidone treatment on prolactin levels in children and adolescents withautism. Biol Psychiatry 61:545-550, 2007.
6. Barzman DH, DelBello MP, Kowatch RA, Garnert B, Fleck DE, Pathak S, Rappaport K, Delgado SV, Campbell P, Strakowski SM: The effectiveness and tolerability of aripiprazole for pediatric bipolar disorder: A retrospective chart review. J ChildAdolesc Psychopharmacol 14:593-600, 2004.
7. Biederman J, McDonnell MA, Wozniak J, Spencer T, Aleardi M, Falzone R, Mick E: Aripiprazole in the treatment of pediatric bipolar disorder: A systematic chart review. CNS Spectr10:141-148, 2005.
8. Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P, Kotarski M, Aleardi M, Wozniak J: An open-label trial of aripiprazole monotherapy in children and adolescents withbipolar disorder. CNS Spectr 12:683-689, 2007.
9. Brown EC, Aman MG, Havercamp SM: Factor analysis and norms on parent ratings with the Aberrant Behavior Checklist: Community for young people in special education. Res DevDisabil 23:45-60, 2002.
10. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.J Pharmacol Exp Ther 302:381-389, 2002.
11. Chang KD, Nyilas M, Aurang C, Johnson MS, Jin N, Marcus R, Forbes RA, Carson WH, Kahn A, Findling RL: Efficacy of aripiprazole in children (10-17 years old) with mania. Boston (MA): 54th American Academy of Child and Adolescent Psychiatry Meeting, 2007 (poster).
12. Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents.J Am Acad Child Adolesc Psychiatry 45:771-791, 2006.
13. Correll CU, Nyilas M, Aurang C, Johnson B, Jin N, Marcus R, Pikalov A, McQuade RD, Iwamoto T, Weller E: Safety and tolerability of aripiprazole in children (10-17) with mania. Boston (Massachusetts): 54th American Academy of Child and Adolescent Psychiatry Meeting, 2007 (poster).
14. Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ: A retrospective analysis of quetiapine in the treatment of pervasivedevelopmental disorders. J Clin Psychiatry 65:1531-1536, 2004.
15. Dawson JE, Matson JL, Cherry KE: An analysis of maladaptive behaviors in persons with autism, PDD NOS, and mental retardation.Res Dev Disabil 19:439-448, 1998.
16. Dawson G, Webb S, Shellenberg GD, Dager S, Friedman S, Aylward E, Richards T: Defining the broader phenotype of autism: Genetic, brain, and behavioral perspectives. DevPsychopathol 14:581-611, 2002.
17. De Rocha FF Correa H: Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder (letter to the editor). Prog NeuropsychopharmacolBiol Psychiatry 31:1550-1551, 2007.
18. Findling RL, Maxwell K, Wiznitzer M: An open clinical trial of risperidone monotherapy in young children with autisticdisorder. Psychopharmacol Bull 33:155-159, 1997.
19. Findling RL, McNamara NK, Gracious BL, O'Riordan MA, Reed MD, Demeter C, Blumer JL: Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 14:287-294, 2004.
20. Findling RL, Robb AS, Nyilas M, Forbes RA, McQuade RD, Mallikaarjun S, Pikalov A: Tolerability of aripiprazole in the treatment of adolescents with schizophrenia. San Diego (California): American Psychiatric Association 160th Annual Meeting, 2007 (poster).
21. Fombonne E: Epidemiology of autistic disorder and other pervasive developmental disorders. J Clin Psychiatry 66(Suppl 10):3-8, 2005.
22. Friedman S, Abdallah TA, Oumaya M, Rouillon F, Guelfi JD: Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder (letter to the editor). J ClinPsychiatry 68:972-973, 2007.
23. Guy W: ECDEU assessment manual for psychopharmacology (NIMH Publication No. 76-338). Washington (DC): DHEW,NIMH, 1976.
24. Hardan AY, Jou RJ, Handen BL: Retrospective study of quetiapine in children and adolescents with pervasive developmentaldisorders. J Autism Dev Disord 35:387-391, 2005.
25. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at thehuman 5-HT1A receptor. Eur J Pharmacol 441:137-140, 2002.
26. Littell RC, Milliken GA, Stroup WW, Wolfinger RD: SAS system for mixed models. Cary: SAS Inst. Inc., 1996, pp 31-63.
27. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA: Olanzapine versus haloperidol in children with autistic disorder: An open-pilot study. J Am Acad Child Adolesc Psychiatry40:887-894, 2001.
28. Malone RP, Delaney MA, Hyman SB, Cater JR: Ziprasidone in adolescents with autism: An open-label pilot study. J ChildAdolesc Psychopharmacol 17:779-790, 2007.
29. Martin A, Koenig K, Scahill L, Bregman J: Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9:99-107, 1999.
30. Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CJ, Tierney E, Chuang S, Vitiello B; The Research Units on Pediatric Psychopharmacology Autism Network: Weight and leptin changes among risperidonetreated youths with autism: 6-month prospective data. Am JPsychiatry 161:1125-1127, 2004.
31. Masi G, Cosenza A, Mucci M, Brovedani P: Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 40:1206-1214, 2001.
32. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ: Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. J Am Acad Child AdolescPsychiatry 36:685-693, 1997.
33. McDougle CJ, Kem DL, Posey DJ: Case series: Use of ziprasidone for maladaptive symptoms in youths with autism. J AmAcad Child Adolesc Psychiatry 41:921-927, 2002.
34. McDougle CJ, Erickson CA, Stigler KA, Posey DJ: Neurochemistry in the pathophysiology of autism. J Clin Psychiatry66(Suppl):9-18, 2005.
35. McDougle CJ, Posey DJ, Stigler KA: Pharmacological treatments. In: Understanding Autism: From Basic Neuroscience to Treatment. Edited by Moldin SO, Rubenstein JLR. Boca Raton: CRC Press, 2006, pp 417-442.
36. Millan MJ: Improving the treatment of schizophrenia: Focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 295:853-861, 2000.
37. Nicolson R, Awad G, Sloman L: An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry41:921-927, 1998.
38. Nyilas M, Chang K, Forbes RA, Jin N, Johnson B, Owen R, Pikalov A, McQuade RD, Iwamoto T, Carson WH: Acute efficacy and tolerability of the treatment of bipolar I disorder in pediatric patients. Washington (DC): American Psychiatric Association 161st Annual Meeting, 2008 (poster).
39. Owen R, Findling RL, Carlson G, Nyilas M, Iwamoto T, Mankoski R, Assuncao-Talbott S, Carson WH, McQuade R, Oren DA: Efficacy and safety of aripiprazole in the treatment of serious behavioral problems associated with autistic disorder in children and adolescents (6-17 years old): Results from a double-blind, randomized, placebo-controlled trial. Chicago (Illinois): 55th American Academy of Child and Adolescent Psychiatry Meeting, 2008a (poster).
40. Owen R, Marcus R, Aman MG, Manos G, Mankoski R, Assuncao-Talbott S, Nyilas M, Iwamoto T, Carson W, Oren DA: Efficacy and safety of aripiprazole in the treatment of serious behavioral problems associated with autistic disorder in children and adolescents (6-17 years old): Results from a fixed-dose, double-blind, randomized, placebocontrolled trial. Chicago (Illinois): 55th American Academy of Child and Adolescent Psychiatry Meeting, 2008b (poster).
41. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. J ClinPsychopharmacol 19:37-44, 1999.
42. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Risperidone in children with autism and seriousbehavioral problems. N Engl J Med 347:314-321, 2002.
43. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Risperidone treatment of autistic disorder: Longer term benefits and blinded discontinuation after 6months. Am J Psychiatry 162:1361-1369, 2005.
44. Robb AS, Findling RL, Nyilas M, Forbes R, McQuade RD, Mallikaarjun S, Pikalov A, Marcus R, Carson WH: Efficacy of aripiprazole in the treatment of adolescents with schizophrenia. San Diego (California): American Psychiatric Association 160th Annual Meeting, 2007 (poster).
45. Roid GH, Miller LJ: Leiter International Performance Scale-Revised. Wood Dale (Illinois): Stoelting Company, 1997.
46. Scahill L, McDougle CJ, Williams SK, Dimitropoulos A, Aman MG, McCracken JT, Tierney E, Arnold LE, Cronin P, Grados M, Ghuman J, Koenig K, Lam KS, McGough J, Posey DJ, Ritz L, Swiezy NB, Vitiello B; Research Units on Pediatric Psychopharmacology Autism Network: Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry45:1114-1123, 2006.
47. Seo WS, Sung HM, Sea HS, Bai DS: Aripiprazole treatment of children and adolescents with Tourette disorder or chronic ticdisorder. J Child Adolesc Psychopharmacol 18:197-205, 2008.
48. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F: Risperidone treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmentaldisorders. Pediatrics 114:e634-e641, 2004.
49. Simpson GM, Angus JW: A rating scale for extrapyramidal sideeffects. Acta Psychiatr Scand Suppl 212:11-19, 1970.
50. Sparrow SS, Cicchetti DV, Balla DA: Vineland Adaptive Behavior Scales, Second Edition (Vineland II), Survey Interview Form/Caregiver Rating Form. Livonia (Minnesota): PearsonAssessments, 2005.
51. Stigler KA, Posey DJ, McDougle CJ: Recent advances in the pharmacotherapy of autism. Expert Rev Neurotherapeutics2:499-510, 2002.
52. Stigler KA, Posey DJ, McDougle CJ: Aripiprazole for maladaptive behavior in pervasive developmental disorders. J ChildAdolesc Psychopharmacol 14:455-463, 2004.
53. Storch EA, Lehmkuhl H, Gefken GR, Touchton A, Murphy TK: Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder.Depression and Anxiety 25:172-174, 2008.
54. Tamminga CA: Partial dopamine agonists in the treatment ofpsychosis. J Neural Transm 109:411-420, 2001.
55. Towbin KE: Pervasive developmental disorder not otherwise specified. In: Handbook of Autism and Pervasive Developmental Disorders. Edited by Volkmar FR, Paul R, Klin A, Cohen D. New York: John Wiley & Sons, 2005, pp 165-200.
56. Valicenti-McDermott MR, Demb H: Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child AdolescPsychopharmacol 16:549-560, 2006.
57. Wagner KD, Nyilas M, Johnson B, Aurang C, Forbes A, Marcus R, Carson WH, Iwamoto T, Carlson GA: Long-term efficacy of aripiprazole in children (10-17 years old) with mania. Boston (Massachusetts): 54th American Academy of Child and Adolescent Psychiatry Meeting, 2007 (poster).
58. Wechsler D: Wechsler Intelligence Scale for Children, 3rd edition.San Antonio (Texas): Psychological Corporation, 1999.
59. Williams SK, Scahill L, Vitiello B,AmanMG,Arnold LE,McDougle CJ, McCracken JT, Tierney E, Ritz L, Posey DJ, Swiezy NB, Hollway J, Cronin P, Ghuman J, Wheeler C, Cicchetti D, Sparrow S: Risperidone and adaptive behavior in children with autism.J Am Acad Child Adolesc Psychiatry 45:431-439, 2006.
60. Yoo HK, Kim JY, Kim CY: Letter to the Editor: A pilot study of aripiprazole in children and adolescents with Touretté disorder.J Child Adolesc Psychopharmacol 16:505-506, 2006.
61. Yoo HK, Choi SH, Park S, Wang HR, Hong JP, Kim CY: An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry68:1088-1093, 2007.